Cartesian Therapeutics, Inc.
RNACHealthcare|Biotechnology|US
$7.53
+0.75 (+11.06%)
DCF Value
$3.97
Cash / Share
$4.06
Clinical Trials (12)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06799247 Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Myasthaenia Gravis | P3 | Active | 128 | RCT, Double-blind | Decartes-08 |
| NCT06038474 Descartes-08 for Patients With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | P2 | Active | 6 | Open-label | Descartes-08 |
| NCT07391605 Descartes-08 in Autoantibody Myositis | Antisynthetase Syndrome | P2 | Recruiting | 60 | RCT, Double-blind | Descartes-08 |
| NCT04146051 Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | Myasthenia Gravis, Generalized | P2 | Active | 30 | RCT, Double-blind | Descartes-08 |
| NCT07089121 Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders | Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) | P1P2 | Recruiting | 50 | Open-label | Descartes-08 |
| NCT04816526 Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | Myeloma Multiple | P2 | Terminated | 13 | Open-label | Descartes 08 |
| NCT04436029 Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | Multiple Myeloma | P2 | Completed | 5 | Open-label | Descartes 11 |
| NCT03448978 Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | Multiple Myeloma | P1 | Terminated | 32 | Open-label | Descartes-08, Fludarabine, Cyclophosphamide |
| NCT05113342 Descartes-25 in Relapsed/Refractory Multiple Myeloma | Multiple Myeloma, Relapse Multiple Myeloma | P1 | Terminated | 9 | Open-label | Descartes-25 |
| NCT04524962 Study of Descartes-30 in Acute Respiratory Distress Syndrome | Acute Respiratory Distress Syndrome, Covid19 | P1 | Terminated | 12 | Open-label | Descartes 30 |
| NCT03994705 Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | P1 | Terminated | 20 | Open-label | Descartes-11, Fludarabine, Cyclophosphamide |
| NCT06304636 Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma | Refractory Multiple Myeloma, Relapsed Multiple Myeloma | P1 | Terminated | 4 | Open-label | Descartes-15 |